Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cybin Inc.
< Previous
1
2
3
4
5
6
Next >
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
August 13, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
August 08, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
June 26, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 19, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
June 11, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
May 29, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
May 14, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
May 06, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate at the 27th Annual Milken Institute Global Conference
April 25, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
April 18, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
April 16, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 10, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
March 18, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
March 15, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
March 14, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
March 13, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
March 12, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
February 14, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
February 07, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
January 23, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
January 08, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs
January 04, 2024
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
December 06, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
December 05, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
November 30, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
November 20, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023
November 16, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
November 15, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.